{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:25:04Z","timestamp":1766269504819,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chunhui Project Foundation of the Education Department of China Grant","award":["HZKY20220176"],"award-info":[{"award-number":["HZKY20220176"]}]},{"name":"Jiangsu Province Hospital Clinical Capacity Enhancement Project","award":["JSPH-MC-2022-18"],"award-info":[{"award-number":["JSPH-MC-2022-18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04539-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:52:18Z","timestamp":1761745938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Yanni","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4874-9171","authenticated-orcid":false,"given":"Buyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"3","key":"4539_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u201372.","journal-title":"N Engl J Med"},{"issue":"10314","key":"4539_CR2","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Saussele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326.","journal-title":"Lancet"},{"issue":"1","key":"4539_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4539_CR4","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191\u2013212.","journal-title":"Am J Hematol"},{"issue":"3","key":"4539_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1056\/NEJMct071828","volume":"357","author":"CA Schiffer","year":"2007","unstructured":"Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258\u201365.","journal-title":"N Engl J Med"},{"issue":"23","key":"4539_CR6","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/cncr.35038","volume":"129","author":"K Sasaki","year":"2023","unstructured":"Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the united States since the introduction of Imatinib therapy-The Surveillance, Epidemiology, and end results database, 2000\u20132019. Cancer. 2023;129(23):3805\u201314.","journal-title":"Cancer"},{"issue":"10","key":"4539_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, et al. Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"4539_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipina JJ, Kim DW, Ogura M, et al. Dasatinib or Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"24","key":"4539_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"4539_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, et al. Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4539_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"2","key":"4539_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"G Smith","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, Goringe A, Rao A, Khorashad J, de Lavallade H, et al. A British society for haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191(2):171\u201393.","journal-title":"Br J Haematol"},{"key":"4539_CR13","doi-asserted-by":"crossref","unstructured":"Benkhadra M, Ghasoub R, Hajeomar R, Alshurafa A, Qasem NM, Saglio G, Cortes J, Elkonaissi I, Kaddoura R, Yassin MA. Caught in the crossfire: unmasking the silent renal threats of tyrosine kinase inhibitors in chronic myeloid leukemia. Cancers (Basel). 2024;17(1).","DOI":"10.3390\/cancers17010092"},{"issue":"1","key":"4539_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","volume":"2","author":"KD Jhaveri","year":"2017","unstructured":"Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review. Kidney Int Rep. 2017;2(1):108\u201323.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4539_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015;11(6):354\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"4539_CR16","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1016\/S2352-3026(23)00164-3","volume":"10","author":"HM Kantarjian","year":"2023","unstructured":"Kantarjian HM, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol. 2023;10(10):e860\u20134.","journal-title":"Lancet Haematol"},{"issue":"7","key":"4539_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-019-03690-2","volume":"98","author":"X Ren","year":"2019","unstructured":"Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627\u201340.","journal-title":"Ann Hematol"},{"issue":"1","key":"4539_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","volume":"27","author":"L Zhang","year":"2021","unstructured":"Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, et al. Flumatinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: A phase III, Randomized, Open-label, Multi-center festnd study. Clin Cancer Res. 2021;27(1):70\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4539_CR19","first-page":"14","volume":"32","author":"Q Li","year":"2024","unstructured":"Li Q, Jing L, Wu PQ, Han LY, Xing HY, Huang CL. Clinical efficacy and safety of Flumatinib in the treatment of patients with newly diagnosed chronic myeloid leukemia in chronic Phase. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):14\u20139.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"4539_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40264-019-00873-8","volume":"43","author":"TM Patek","year":"2020","unstructured":"Patek TM, Teng C, Kennedy KE, Alvarez CA, Frei CR. Comparing acute kidney injury reports among antibiotics: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Drug Saf. 2020;43(1):17\u201322.","journal-title":"Drug Saf"},{"key":"4539_CR21","doi-asserted-by":"publisher","first-page":"109350","DOI":"10.1016\/j.intimp.2022.109350","volume":"113Pt A","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wu J, Chen P, You K, Su J, Gao Z, Bi Z, Feng M. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study. Int Immunopharmacol. 2022;113Pt A:109350.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4539_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting False-Positive associations. Drug Saf. 2020;43(5):479\u201387.","journal-title":"Drug Saf"},{"issue":"12","key":"4539_CR23","first-page":"3965","volume":"109","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu Y, Sun H, Meng L, Lin H, Chen C, Hu J, Shen X, Duan M, Zhang Y, et al. Safety and efficacy of Flumatinib as later-line therapy in patients with chronic myeloid leukemia. Haematologica. 2024;109(12):3965\u201374.","journal-title":"Haematologica"},{"issue":"8","key":"4539_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1124\/dmd.110.032326","volume":"38","author":"A Gong","year":"2010","unstructured":"Gong A, Chen X, Deng P, Zhong D. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010;38(8):1328\u201340.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4539_CR25","first-page":"14","volume":"32","author":"YY Li","year":"2024","unstructured":"Li YY, Wang CL. Real-World efficacy and safety of China-Made Flumatinib mesylate in the treatment of chronic myeloid leukemia in chronic Phase. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):14\u20139.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"4539_CR26","doi-asserted-by":"crossref","unstructured":"Cellier M, Bourneau-Martin D, Abbara C, Crosnier A, Lagarce L, Garnier AS, Briet M. Renal safety profile of BCR-ABL tyrosine kinase inhibitors in a real-life setting: a study based on vigibase((R)), the WHO pharmacovigilance database. Cancers (Basel). 2023;15(7).","DOI":"10.3390\/cancers15072041"},{"issue":"1","key":"4539_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0002-9440(10)63651-6","volume":"163","author":"M Takikita-Suzuki","year":"2003","unstructured":"Takikita-Suzuki M, Haneda M, Sasahara M, Owada MK, Nakagawa T, Isono M, Takikita S, Koya D, Ogasawara K, Kikkawa R. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol. 2003;163(1):277\u201386.","journal-title":"Am J Pathol"},{"issue":"21","key":"4539_CR28","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonzalez GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121(21):3894\u2013904.","journal-title":"Cancer"},{"issue":"2","key":"4539_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","volume":"51","author":"H Francois","year":"2008","unstructured":"Francois H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P. Partial Fanconi syndrome induced by Imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis. 2008;51(2):298\u2013301.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4539_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"4539_CR31","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NCD, Macedo AV, Marx-Neto AD, Silva M, van Gelder T, Akkerhuis KM, Ribeiro AL. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22(9):2073\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"4539_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/jha2.988","volume":"5","author":"ZS Ayalew","year":"2024","unstructured":"Ayalew ZS, Azibte GT, Tadesse F, Legesse BA, Kiflu ZG, Weldeamanuel MT, Tsige KA, Molla BA, Ejigu AM. Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. EJHaem. 2024;5(4):749\u201356.","journal-title":"EJHaem"},{"issue":"20","key":"4539_CR33","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, et al. Final 5-Year study results of DASISION: the dasatinib versus Imatinib study in Treatment-Naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4539_CR34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103(8):1298\u2013307.","journal-title":"Haematologica"},{"issue":"7","key":"4539_CR35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Brummendorf","year":"2022","unstructured":"Brummendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, et al. Bosutinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"21","key":"4539_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gomez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, et al. Ponatinib vs Imatinib in frontline Philadelphia Chromosome-Positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"1","key":"4539_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","volume":"34","author":"A Gafter-Gvili","year":"2010","unstructured":"Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. Renal failure associated with tyrosine kinase inhibitors\u2013case report and review of the literature. Leuk Res. 2010;34(1):123\u20137.","journal-title":"Leuk Res"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04539-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:03:22Z","timestamp":1761786202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4539"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04539-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the First Affiliated Hospital Ethics Committee of Nanjing Medical University. Individual consent in the pharmacovigilance study was not needed because the data were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient to publish this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"604"}}